Efficacy and safety of Mobi-C cervical artificial disc versus anterior discectomy and fusion in patients with symptomatic degenerative disc disease
A meta-analysis
Hui Lu, MD\textsuperscript{a}, Lihua Peng, MD\textsuperscript{b}\textsuperscript{*}

Abstract
Background: Total disc replacement (TDR) using Mobi-C cervical artificial disc might be promising to treat symptomatic degenerative disc disease. However, the results remained controversial. We conducted a systematic review and meta-analysis to compare the efficacy and safety of Mobi-C cervical artificial disc and anterior cervical discectomy and fusion (ACDF) in patients with symptomatic degenerative disc disease.

Methods: PubMed, Embase, Web of science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of Mobi-C versus ACDF on the treatment of symptomatic degenerative disc disease were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. The primary outcomes were neck disability index (NDI) score, patient satisfaction, and subsequent surgical intervention. Meta-analysis was performed using the random-effect model.

Results: Four RCTs were included in the meta-analysis. Overall, compared with ACDF surgery for symptomatic degenerative disc disease, TDR using Mobi-C was associated with a significantly increased NDI score (Std. mean difference $= 0.32$; 95\% CI $= 0.10$–0.53; $P = .004$), patient satisfaction (odds risk [OR] $= 2.75$; 95\% confidence interval [CI] $= 1.43$–5.27; $P = .002$), and reduced subsequent surgical intervention (OR $= 0.20$; 95\% CI $= 0.11$–0.37; $P < .001$). Mobi-C was found to produce comparable neurological deterioration (OR $= 0.77$; 95\% CI $= 0.35$–1.72; $P = .53$), radiographic success (OR $= 1.18$; 95\% CI $= 0.39$–3.59; $P = .77$), and overall success (OR $= 2.13$; 95\% CI $= 0.80$–5.70; $P = .13$) compared with ACDF treatment.

Conclusion: Among the 4 included RCTs, 3 articles were studying patients with 1 surgical level, and 1 article reported 2 surgical levels. When compared with ACDF surgery in symptomatic degenerative disc disease, TDR using Mobi-C cervical artificial disc resulted in a significantly improved NDI score, patient satisfaction, and reduced subsequent surgical intervention. There was no significant difference of neurological deterioration, radiographic success, and overall success between TDR using Mobi-C cervical artificial disc versus ACDF surgery. TDR using Mobi-C cervical artificial disc should be recommended for the treatment of symptomatic degenerative disc disease.

Abbreviations: ACDF = artificial disc and anterior cervical discectomy and fusion, HO = heterotopic ossification, NDI = neck disability index, NSAIDs = nonsteroidal anti-inflammatory drugs, RCTs = randomized controlled trials, Std. MDs = standard mean differences, TDR = total disc replacement.

Keywords: anterior cervical discectomy and fusion (ACDF), cervical artificial disc, meta-analysis, Mobi-C, symptomatic degenerative disc disease

Editor: Nicandro Figueredo.

Authors’ contributions: Hui Lu and Lihua Peng conduct the design, article search, data analysis, interpretation of data, and write this paper.

Ethics approval and consent to participate: not applicable.

Consent for publication: not applicable.

Ethical approval: No ethical approval was needed because this meta-analysis was performed based on previous randomized controlled studies.

Availability of data and materials: Please contact author for data requests. Competing interests: The authors declare that they have no competing interests.

Funding: Not applicable.

No conflicts of interest to disclose.

\textsuperscript{a} Department of Orthopaedics, Jiangjin Central Hospital of Chongqing, \textsuperscript{b} Department of Orthopaedics, The People’s Hospital of Bishan District, Chongqing, P.R. China.

Correspondence: Lihua Peng, The People’s Hospital of Bishan District, Chongqing, China (e-mail: 363670397@qq.com)

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Medicine (2017) 96(49):e8504

Received: 12 April 2017 / Received in final form: 30 September 2017 / Accepted: 3 October 2017

https://dx.doi.org/10.1097/MD.0000000000008504
1. Introduction

Anterior cervical discectomy and fusion (ACDF) was widely accepted as the standard surgical treatment for symptomatic radiculopathy and myelopathy caused by degenerative disc disease.[1–3] But it could result in adjacent-segment degeneration because of the elimination of natural motion of treated segments and improved intradiscal pressures at adjacent levels.[4–7] Total disc replacement (TDR) was able to preserve treated segment natural motion as well as overall cervical spine biomechanics and might alleviate symptomatic radiculopathy and myelopathy, and avoid exacerbating adjacent segment degeneration.[8,9]

There have been many clinical studies reporting the clinical outcome of cervical TDR versus ACDF. Results showed cervical TDR could produce outcomes similar or superior to ACDF, and the results were consistent ranging from 1 to 5 years of follow-up.[10–14] Cervical TDR was associated with a significantly lower reoperation rate[11] as well as reduced occurrence of adjacent segment degeneration in relative to ACDF.[10,16] But, adjacent segment degeneration was found to have no significant difference between cervical TDR and ACDF.[9]

The Mobi-C cervical artificial disc (LDR Medical; Troyes, France) is a semiconstrained, mobile bearing, bone-sparing TDR consisting of 2 cobalt–chromium–molybdenum alloy endplates and an ultra-high-molecular-weight polyethylene mobile insert facilitating 5 independent degrees of freedom.[17] Clinical studies reported cervical TDR using Mobi-C significantly improved neck disability index (NDI) score, patient satisfaction, overall success, and reduced subsequent surgical intervention compared with ACDF.[9,18]

In contrast, some relevant randomized controlled trials (RCTs) showed that compared with ACDF treatment for symptomatic degenerative disc disease, cervical TDR using Mobi-C failed to significantly improve NDI scores, patient satisfaction, overall success, and decrease neurological deterioration.[9,19] Considering these inconsistent effects, we therefore conducted a systematic review and meta-analysis of RCTs to compare the efficacy and safety of Mobi-C cervical artificial disc and ACDF for the treatment of symptomatic degenerative disc disease.

2. Materials and methods

This systematic review and meta-analysis were conducted according to the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement[20] and the Cochrane Handbook for Systematic Reviews of Interventions.[21]

2.1. Literature search and selection criteria

PubMed, EMbase, Web of science, EBSCO, and the Cochrane library were systematically searched from inception to December 2016, with the following keywords: Mobi-C, and anterior cervical discectomy, and fusion or ACDF. To include additional eligible studies, the reference lists of retrieved studies and relevant reviews were also hand-searched and the process above was performed repeatedly until no further article was identified.

The inclusion criteria were as follows: the study population were patients with symptomatic degenerative disc disease; intervention treatment was TDR using Mobi-C versus ACDF; and study design was RCT.

The exclusion criteria included any prior spine surgery at operative level, Paget disease, osteomalacia, or any other metabolic bone disease other than osteoporosis.

2.2. Data extraction and outcome measures

The following information was extracted for the included RCTs: first author, publication year, sample size, baseline characteristics of patients, intervention of TDR using Mobi-C, intervention of control, study design, NDI score, patient

---

Figure 1. Flow diagram of study searching and selection process.
| Study Author-Year | No. author | No. of included studies | Number of patients | NDI score | Patient satisfaction | Subsequent surgical intervention | Neurological deterioration | Radiographic success | Overall success | Adverse events |
|-------------------|-----------|------------------------|-------------------|-----------|---------------------|-------------------------------|------------------------|-------------------|----------------|---------------|
| Hou 2016          | 51        | 46.3 ± 7.8             | 21                | 55 (65.8%) | 20 (70.6%)          | 12 (46.3%)                    | 0                      | 0                 | 0              | 0             |
| Husey 2016        | 164       | 43.3 ± 9.2             | 27.3 ± 4.4        | 108 (65.9%) | 70 (77.1%)          | 112 (91.1%)                   | 0                      | 0                 | 0              | 0             |
| Reginald 2015     | 225       | 45.3 ± 8.1             | 27 ± 4.5          | 141 (62.7%) | 64 (56.8%)          | 46 (40.4%)                    | 0                      | 0                 | 0              | 0             |
| Park 2008         | 21        | 45 (31–61)             | –                 | –          | –                   | –                             | –                      | –                 | –              | –             |

ACDF = artificial disc and anterior cervical discectomy and fusion, BMI = body mass index, NASS = North American Spine Society.

The Jadad Scale was used to evaluate the methodological quality of each RCT included in this meta-analysis. This scale consisted of 3 evaluation elements: randomization (0–2 points), blinding (0–2 points), dropouts and withdrawals (0–1 points). One point would be allocated to each element if they have been mentioned in article, and another one point would be given if the methods of randomization and/or blinding had been detailedly and appropriately described. If methods of randomization and/or blinding were inappropriate, or dropouts and withdrawals had not been recorded, then one point was deducted. The score of Jadad Scale varies from 0 to 5 points. An article with Jadad score ≤ 2 was considered to be of low quality. If the Jadad score ≥ 3, the study was thought to be of high quality.

2.4. Statistical analysis

Standard mean differences (Std. MDs) with 95% confidence intervals (CIs) for continuous outcomes (NDI score) and odds risks (ORs) with 95% CIs for dichotomous outcomes (patient satisfaction, subsequent surgical intervention, neurological deterioration, radiographic success, overall success) were used to estimate the pooled effects. All meta-analyses were performed using random-effects models with DerSimonian and Laird weights. Heterogeneity was tested using the Cochran Q statistic \((P < .1)\) and quantified with the I² statistic, which describes the variation of effect size that was attributable to heterogeneity across studies. An I² value >50% indicated significant heterogeneity. Sensitivity analysis was performed to detect the influence of a single study on the overall estimate via omitting one study in turn when necessary. Owing to the limited number of included studies, publication bias was not assessed. \(P < .05\) in two-tailed tests was considered statistically significant. All statistical analyses were performed with Review Manager Version 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK).
3. Results

3.1. Literature search, study characteristics, and quality assessment

Five hundred sixteen potential studies were obtained through the initial search of databases. The detailed screening flow was shown in Fig. 1. Three hundred eighty nine studies were excluded after screening the titles and abstracts. Four RCTs were included in the meta-analysis.\(^9,18,19,24\)

Table 1 demonstrated detailed characteristics of 4 included studies in this meta-analysis. Their sample sizes ranged from 53 to 330, and the total number was 727. There were similar age, body mass index (BMI), work status, and driving status in patients at baseline. Of these 4 RCTs, 3 studies reported 1-level disc\(^9,19,24\) and 1 study reported 2-level discs\(^18\) for surgery. The follow-up time varied from 1 year to 3 years.

Among the 4 RCTs, 2 studies reported the NDI score,\(^18,19\) 2 studies reported the patient satisfaction,\(^9,18\) 3 studies reported the subsequent surgical intervention,\(^9,18,19\) 2 studies reported the neurological deterioration, radiographic success, and overall success,\(^9,18\) Jadad scores of the 4 included studies varied from 3 to 4. North American Spine Society (NASS) grades of all included RCTs were level I. These indicated that all 4 studies were considered to be high-quality and well-designed ones.\(^25\)

3.2. Primary outcome: NDI score, patient satisfaction, and subsequent surgical intervention

The random-effects model was applied to analyze these 3 outcome data. These 3 outcome data were analyzed with a random-effects model. Compared with ACDF for symptomatic degenerative disc disease, TDR using Mobi-C could significantly increase NDI score (Std. mean difference = 0.32; 95% CI = 0.10–0.53; \(P = .004\)) after pooling the results of 2 included RCTs, with low heterogeneity among the studies (\(I^2 = 1\%, \text{ heterogeneity } P = .31\)) (Fig. 2). TDR using Mobi-C was also found to significantly improve patient satisfaction (OR = 2.75; 95% CI = 1.43–5.27; \(P = .002\)) than ACDF, with no heterogeneity among the studies (\(I^2 = 0\%, \text{ heterogeneity } P = .47\)) (Fig. 3). Consistently, the incidence of subsequent surgical intervention was revealed to be significantly lower in Mobi-C group than that in ACDF group (OR = 0.20; 95% CI = 0.11–0.37; \(P < .001\)) than ACDF, with no heterogeneity among the studies (\(I^2 = 0\%, \text{ heterogeneity } P = .87\)) (Fig. 4).

| Study or Subgroup | Mobi-C group | ACDF group | Std. Mean Difference | M-H. Random 95% CI |
|-------------------|--------------|------------|----------------------|---------------------|
|                    | Mean (SD)    | Total (SD) | Total (SD)           |                     |
| Hou 2016           | 19.7 (8.1)   | 51 (20.0)  | 85 (20.0)            | 0.09 (0.25, 0.54)   |
| Regnold 2015       | 36.5 (22.3)  | 200 (28.5) | 87 (20.2)            | 0.13 (0.03, 0.23)   |
| Total (95% CI)     |              | 251        | 133                  | 0.32 (0.10, 0.53)   |
| Heterogeneity: Tau\(^2\) = 0.00; Chi\(^2\) = 1.01, df = 1 (\(P = .31\)); P = 1% |
| Test for overall effect: Z = 2.88 (P = .004) |

---

Figure 2. Forest plot for the meta-analysis of NDI score. NDI scores ranged from 0 to 50. NDI = neck disability index.

Figure 3. Forest plot for the meta-analysis of patient satisfaction. Patient satisfaction was tested by a questionnaire: very satisfied, somewhat satisfied, somewhat dissatisfied, or very dissatisfied with their treatment.

Figure 4. Forest plot for the meta-analysis of subsequent surgical intervention. Subsequent surgical intervention was defined as any secondary surgery at an index-level segment and included removal, revision, supplemental fixation, or reoperation, but did not included adjacent-level subsequent surgeries.
3.3. Sensitivity analysis

Low heterogeneity or no heterogeneity was observed among the included studies for NDI score, patient satisfaction, and subsequent surgical intervention. Thus, we did not perform sensitivity analysis by omitting one study in each turn to detect the source of heterogeneity.

3.4. Secondary outcomes

Compared with ACDF treatment, TDR using Mobi-C artificial disc resulted in comparable neurological deterioration (OR = 0.77; 95% CI = 0.35–1.72; P = .53; Fig. 5) and achieve comparable radiographic success (OR = 1.18; 95% CI = 0.39–3.59; P = .77; Fig. 6), and overall success (OR = 2.13; 95% CI = 0.80–5.70; P = .13; Fig. 7).

3.5. Adverse effects

Device-related adverse events were defined as any clinically adverse sign, symptom, syndrome, or illness that occurred or worsened during or after the initial surgery, and were caused by TDR using Mobi-C artificial disc or ACDF. These adverse events mainly included malpositioned implant, cage subsidence, heterotopic ossification, wound infection, non-union, etc. There was no significant difference of device-related adverse events between Mobi-C group and ACDF group after pooling the results of 3 included studies (OR = 0.61; 95% CI = 0.18–2.10; P = .43; Fig. 8).

4. Discussion

Our meta-analysis clearly suggested that compared with ACDF treatment for symptomatic degenerative disc disease, TDR using Mobi-C cervical artificial disc was associated with a significantly improved NDI score, patient satisfaction, and reduced subsequent surgical intervention, and resulted in comparable neurological deterioration, radiographic success, and overall success. Similar device-related adverse events were found between Mobi-C group and ACDF group. This was the first meta-analysis to study the treatment efficacy of TDR using Mobi-C cervical artificial disc versus ACDF in patients with symptomatic degenerative disc disease.

Two included study also showed that TDR using Mobi-C cervical artificial disc demonstrated statistically better results of SF-12 PCS scores, pain alleviation, and adjacent-segment degeneration than ACDF treatment.\(^\text{[9,18]}\) These results were consistent with trials comparing TDR using other cervical artificial disc with ACDF.\(^\text{[13,26]}\) Adjacent-segment degeneration was the major concern for patients undergoing surgery for degenerative disc disease. ACDF resulted in higher rates of...
adjacent-segment degeneration, and TDR could not entirely prevent adjacent-segment degeneration, but these underlying mechanisms were elusive. It was still widely debated whether the preservation of the adjacent-segment with TDR was due to the preserved biomechanics at the index and adjacent levels.[14,18]

The stable flexion/extension mean range of motion at the operated segment was of significant difference for TDR surgery. Clinically relevant heterotopic ossification (HO) (Grades III and IV) occurred in 16.6% of segments and 25.6% of patients treated with TDR using Mobi-C artificial disc, which was similar to or less than the rates in other cervical artificial disc.[14,18,27] Severe HO was found to significantly limit motion in patients after TDR surgery. Considering that severe HO resulted in essentially fusion, the clinical results may also be similar to ACDF. Various approaches to avoid HO included complete endplate coverage, meticulous surgical technique minimizing uncovered bleeding bone, and prophylactic use of nonsteroidal anti-inflammatory drugs (NSAIDs).[9,14]

There were some potential limitations. Firstly, the test power was limited by sample size. Only 4 RCTs were included in this meta-analysis and 2 of them had a relatively small sample size (n < 100). The follow-up time in the included studies ranged from 1 year to 5 years, and longer follow-up time was needed to evaluate some index including motion and stability of segments, the incidence of HO etc. Different follow-up time and 1 or 2 level symptomatic degenerative disc diseases might affect the pooling results. Next, the mechanisms mediating TDR to reduce adjacent-segment degeneration remained ill clear. Finally, it was unavailable to compare the efficacy and safety of TDR using Mobi-C cervical artificial disc versus ACDF when treating ≥3 level symptomatic degenerative disc diseases.

5. Conclusions

TDR using Mobi-C cervical artificial disc could significantly increase NDI score, patient satisfaction, and decrease subsequent surgical intervention, and obtained comparable neurological deterioration, radiographic success, and overall success compared with ACDF treatment for symptomatic degenerative disc disease. TDR using Mobi-C cervical artificial disc was recommended to be administrated in patients.

References

[1] Brodick DS, Zdeblick TA. Modified Smith-Robinson procedure for anterior cervical discectomy and fusion. Spine (Phila Pa 1976) 1992;17 (Suppl):S427–30.
[2] Cummins BH, Robertson JT, Gill SS. Surgical experience with an implanted artificial cervical joint. J Neurosurg 1998;88:943–8.
[3] Fraser JF, Hartl R. Anterior approaches to fusion of the cervical spine: a metaanalysis of fusion rates. J Neurosurg Spine 2007;6:298–303.
[4] DiAngelo DJ, Roberston JT, Metcalfe NA, et al. Biomechanical testing of an artificial cervical joint and an anterior cervical plate. J Spinal Disord Tech 2003;16:314–23.
[5] Elsawal A, Mastronardi L, Roperto R, et al. Effect of cervical dynamics on adjacent segment degeneration after anterior cervical fusion with cages. Neurosurg Rev 2009;32:215–24, discussion 24.
[6] Kulkarni V, Rajeshkar V, Raghrumam L. Accelerated spondylotic changes adjacent to the fused segment following central cervical corpectomy: magnetic resonance imaging study evidence. J Neurosurg 2004;100(Suppl):2–6.
[7] Robertson JT, Papadopoulos SM, Traynelis VC. Assessment of adjacent-segment disease in patients treated with cervical fusion or arthroplasty: a prospective 2-year study. J Neurosurg Spine 2005;3:917–23.
[8] Prayek JB, Traynelis VC. Treatment of the painful motion segment: cervical arthroplasty. Spine (Phila Pa 1976) 2005;30:523–32.
[9] Hisey MS, Zigler JE, Jackson R, et al. Prospective, randomized comparison of one-level Mobi-C cervical total disc replacement vs. anterior cervical discectomy and fusion: results at 5-year follow-up. Int J Spine Surg 2016;10:10.
[10] Coric D, Nunley PD, Gayer RD, et al. Prospective, randomized, multicenter study of cervical arthroplasty: 269 patients from the Kineflex/C artificial disc investigational device exemption study with a minimum 2-year follow-up: clinical article. J Neurosurg Spine 2011;15:348–58.
[11] Mummaneni PV, Burkus JK, Haid RW, et al. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. J Neurosurg Spine 2007;6:198–209.
[12] Phillips FM, Lee JY, Gesler FH, et al. A prospective, randomized, controlled clinical investigation comparing PBM cervical disc arthroplasty with anterior cervical disc fusion and surgery. 2-year results from the FDA IDE clinical trial. Spine (Phila Pa 1976) 2013;38:E907–18.
[13] Burkus JK, Traynelis VC, Haid RW Jr, et al. Clinical and radiographic analysis of an artificial cervical disc: 7-year follow-up from the Prestige prospective randomized controlled clinical trial: Clinical article. J Neurosurg Spine 2014;21:516–28.
[14] Quan GM, Vital JM, Hansen S, et al. Eight-year clinical and radiological follow-up of the Bryan cervical disc arthroplasty. Spine (Phila Pa 1976) 2011;36:639–46.
[15] Delamarter RB, Zigler J. Five-year reoperation rates, cervical total disc replacement versus fusion, results of a prospective randomized clinical trial. Spine (Phila Pa 1976) 2013;38:711–7.
[16] Hisey MS, Bae HW, Davis R, et al. Multi-center, prospective, randomized, controlled investigational device exemption clinical trial comparing Mobi-C Cervical Artificial Disc to anterior discectomy and fusion in the treatment of symptomatic degenerative disc disease in the cervical spine. Int J Spine Surg 2014:8.
[17] Jackson RJ, Davis RJ, Hofman GA, et al. Subsequent surgery rates after cervical total disc replacement using a Mobi-C cervical disc prosthesis versus anterior cervical discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 5-year follow-up results. J Neurosurg Spine 2016;24:734–45.
[18] Davis RJ, Nunley PD, Kim KD, et al. Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 4-year follow-up results. J Neurosurg Spine 2015;22:15–25.
[19] Hou Y, Nie L, Pan X, et al. Effectiveness and safety of Mobi-C for treatment of single-level cervical disc spondylolisthesis: a randomised control
trial with a minimum of five years of follow-up. Bone Joint J 2016;98-B:829–33.

[20] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.

[21] Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available at: www.cochrane-handbook.org. Accessed March 21, 2011.

[22] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–2.

[23] Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982–9.

[24] Park JH, Roh KH, Cho JY, et al. Comparative analysis of cervical arthroplasty using Mobi-C® and anterior cervical discectomy and fusion using the Solis® -Cage. J Korean Neurosurg Soc 2008;44:217–21.

[25] Kaiser MG, Eck JC, Groff MW, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 1: introduction and methodology. J Neurosurg Spine 2014;21:2–6.

[26] Janssen ME, Zigler JE, Spivak JM, et al. ProDisc-C total disc replacement versus anterior cervical discectomy and fusion for single-level symptomatic cervical disc disease: seven-year follow-up of the prospective randomized U.S. Food and Drug Administration Investigational Device Exemption Study. J Bone Joint Surg Am 2015;97:1738–47.

[27] Suchomel P, Jurak I, Benes V3rd, et al. Clinical results and development of heterotopic ossification in total cervical disc replacement during a 4-year follow-up. Eur Spine J 2010;19:307–15.